Marinova announces record investment in research
Marinova is pleased to report a record annual investment in research and development. For the financial year ending 30 June 2014, the company invested more than 30% of gross revenue into its research and development program. This level of investment represents a significant increase on prior years and will further bolster Marinova’s standing as leader in its field. The company’s R&D program includes targeted studies investigating the bioactivity of Maritech® fucoidans in the areas of oncology, metabolic syndrome and immune modulation. In the past financial year, successful human clinical trials were also undertaken on Marinova’s two skincare ingredients.
Marinova is continually striving to deliver products and services of the highest standard possible. Consolidating the company’s market position necessarily requires an ongoing commitment to quality evidence-based research. In this regard, Marinova will continue to invest heavily in R&D throughout the 2014–15 financial year, expanding its program to include studies of Maritech® fucoidan extracts in areas including gastric health and influenza.